CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 162 enrolled
Drug / intervention
Simultaneous administration of Pneumovax NP® and Fluvic HA syringe® +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02592486
NCT02592486Phase 4Completed
CompareCT.gov

A Randomized, Open-label, Parallel Design Study to Compare the Immunogenicity of Simultaneous Administration Versus Sequential Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine

Kameda Medical Center·interventional·Posted Oct 30, 2015·Updated Jan 31, 2019

In Brief

A Phase 4 clinical trial evaluating Simultaneous administration of Pneumovax NP® and Fluvic HA syringe® and Sequential administration of Pneumovax NP® and Fluvic HA syringe® for Pneumococcal Pneumonia and Influenza. Completed, enrolled 162 participants across 1 site.

Detailed Summary

The immunogenicity of simultaneous administration of quadrivalent influenza vaccine and pneumococcal vaccine was unknown. The purpose of present study is to compare the immunogenicity of simultaneous administration of influenza vaccine and pneumococcal vaccine with that of separate administration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Pneumonia, Influenza
CountriesJapan
CollaboratorsPPD Development, LP, Osaka University, Merck Sharp & Dohme LLC

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 30, 2015
Enrollment StartNov 1, 2015
Primary CompletionMar 1, 2016
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 10.7 years ago

Interventions

Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®biological

Injections of pneumococcal vaccine and influenza vaccine simultaneously.

Sequential administration of Pneumovax NP® and Fluvic HA syringe®biological

Injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine.